Shots:

• Quebec government has stated province intention to shift towards biosimilars and follows the transition policies implemented by British Columbia- Alberta & New Brunswick
• The expanded use of biosimilars is expected to generate annual savings of $100M for the public drug insurance plan and its insured parties that can be reinvested in healthcare and innovative new drugs
• Under the policy- the transition from reference biologic to a biosimilar will take place under the supervision of treated physicians by April 12- 2022

Ref: Quebac| Image: Quebec